Comparison of site-specific PEGylations of the N-terminus of interferon beta-1b: Selectivity, efficiency, and in vivo/vitro activity

Bioconjugate Chemistry

Volumn 25, Issue 1, 2014, Pages 138-146

  Zhou, Zhan ^a,b   Zhang, Jing ^a   Sun, Lijing ^a   Ma, Guanghui ^a   Su, Zhiguo ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDES; CHEMICAL BONDS; GLYCOPROTEINS; PLASMA STABILITY; PROTEINS;

COMPARISON OF SITES; IMMUNOGENICITY; IN-VIVO; INTERFERON BETAS; N TERMINUS; N-TERMINALS; PEGYLATION; SITE-SPECIFIC; VITRO ACTIVITY; VIVO PLASMAS;

AMINO ACIDS;

HYDRAZIDE; INTERFERON BETA SERINE; MACROGOL; BETA INTERFERON; HYDRAZINE DERIVATIVE; MACROGOL DERIVATIVE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; ANIMAL; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COMPARATIVE STUDY; HUMAN; ISOLATION AND PURIFICATION; VERO CELL LINE;

ANIMALS; CERCOPITHECUS AETHIOPS; HUMANS; HYDRAZINES; INTERFERON-BETA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; POLYETHYLENE GLYCOLS; RATS; VERO CELLS;

EID: 84892755064     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc400435u     Document Type: Article

References (42)

1. Wang, Y. J., Hao, S. J., Liu, Y. D., Hu, T., Zhang, G. F., Zhang, X., Qi, Q. S., Ma, G. H., and Su, Z. G. (2010) PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin J. Controlled Release 145, 306-313
2. Pasut, G. and Veronese, F. M. (2009) PEG conjugates in clinical development or use as anticancer agents: An overview Adv. Drug Delivery Rev. 61, 1177-1188
3. Wang, Y. S., Youngster, S., Grace, M., Bausch, J., Bordens, R., and Wyss, D. F. (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Adv. Drug Delivery Rev. 54, 547-570
4. Arakawa, T., Prestrelski, S. J., Narhi, L. O., Boone, T. C., and Kenney, W. C. (1993) Cysteine-17 of recombinant human granulocyte-colony-stimulating factor is partially solvent-exposed J. Protein Chem. 12, 525-531
5. Wang, J., Hu, T., Liu, Y., Zhang, G., Ma, G., and Su, Z. (2011) Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase Anal. Biochem. 412, 114-116
6. Pasut, G. and Veronese, F. M. (2012) State of the art in PEGylation: The great versatility achieved after forty years of research J. Controlled Release 161, 461-472
7. Hu, J. L. and Sebald, W. (2011) N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH Int. J. Pharm. 413, 140-146
8. Kinstler, O. B., Brems, D. N., Lauren, S. L., Paige, A. G., Hamburger, J. B., and Treuheit, M. J. (1996) Characterization and stability of N-terminally PEGylated rhG-CSF Pharm. Res. 13, 996-1002
9. Moosmann, A., Blath, J., Lindner, R., Muller, E., and Bottinger, H. (2011) Aldehyde PEGylation kinetics: A standard protein versus a pharmaceutically relevant single chain variable fragment Bioconjugate Chem. 22, 1545-1558
10. Yu, D. and Ghosh, R. (2010) Purification of PEGylated protein using membrane chromatography J. Pharm. Sci. 99, 3326-3333
11. Geoghegan, K. F. and Stroh, J. G. (1992) Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine Bioconjugate Chem. 3, 138-146
12. Gaertner, H. F. and Offord, R. E. (1996) Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins Bioconjugate Chem. 7, 38-44
13. Lanzillo, R., Orefice, G., Quarantelli, M., Rinaldi, C., Prinster, A., Ventrella, G., Spitaleri, D., Lus, G., Vacca, G., Carotenuto, B., Salvatore, E., Brunetti, A., Tedeschi, G., and Morra, V. B. (2010) Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy Mult. Scler. J. 16, 450-454
14. Conway, D. and Cohen, J. A. (2010) Combination therapy in multiple sclerosis Lancet Neurol. 9, 299-308
15. Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Radu, E. W., Metzig, C., Bauer, L., Lanius, V., Sandbrink, R., and Pohl, C. (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial Lancet Neurol. 8, 987-997
16. Yi, B. R., Park, M. A., Lee, H. R., Kang, N. H., Choi, K. J., Kim, S. U., and Choi, K. C. (2013) Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-beta via their tumor-tropic effect in cellular and xenograft mouse models Mol. Oncol. 7, 543-554
17. Bai, C. Z., Choi, S., Nam, K., An, S., and Park, J. S. (2013) Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma Int. J. Pharm. 445, 79-87
18. Nicolini, A. and Carpi, A. (2005) Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: An exploratory trial Biomed. Pharmacother. 59, 253-263
19. Nikfar, S., Rahimi, R., and Abdollahi, M. (2010) A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type Clin. Ther. 32, 1871-1888
20. Chiang, J., Gloff, C. A., Yoshizawa, C. N., and Williams, G. J. (1993) Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin Pharm. Res. 10, 567-572
21. Hershenson, S. and Thomson, J. (1989) Isoelectric focusing of recombinant interferon-beta Appl. Theor. Electrophor. 1, 123-125
22. Salmaso, S., Semenzato, A., Bersani, S., Mastrotto, F., Scomparin, A., and Caliceti, P. (2008) Site-selective protein glycation and PEGylation Eur. Polym. J. 44, 1378-1389
23. Nairn, N. W., Shanebeck, K. D., Wang, A., Graddis, T. J., VanBrunt, M. P., Thornton, K. C., and Grabstein, K. (2012) Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon beta-1b by site-specific PEGylation Bioconjugate Chem. 23, 2087-2097
24. Basu, A., Yang, K., Wang, M., Liu, S., Chintala, R., Palm, T., Zhao, H., Peng, P., Wu, D., Zhang, Z., Hua, J., Hsieh, M. C., Zhou, J., Petti, G., Li, X., Janjua, A., Mendez, M., Liu, J., Longley, C., Mehlig, M., Borowski, V., Viswanathan, M., and Filpula, D. (2006) Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation Bioconjugate Chem. 17, 618-630
25. Peng, F., Wang, Y., Sun, L., Liu, Y., Hu, T., Zhang, G., Ma, G., and Su, Z. (2012) PEGylation of proteins in organic solution: A case study for interferon beta-1b Bioconjugate Chem. 23, 1812-1820
26. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227, 680-685
27. Lou, J., Chu, G., Zhou, G., Jiang, J., Huang, F., Xu, J., Zheng, S., Jiang, W., Lu, Y., Li, X., Chen, Z., and He, J. (2010) Comparison between two kinds of cigarette smoke condensates (CSCs) of the cytogenotoxicity and protein expression in a human B-cell lymphoblastoid cell line using CCK-8 assay, comet assay and protein microarray Mutat. Res. 697, 55-59
28. Wang, X., Zhang, W., Liu, F., Zheng, M., Zheng, D., Zhang, T., Yi, Y., Ding, Y., Luo, J., Dai, C., Wang, H., Sun, B., and Chen, Z. (2012) Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge Arch. Virol. 157, 1451-1461
29. Clamp, J. R. and Hough, L. (1965) The periodate oxidation of amino acids with reference to studies on glycoproteins Biochem. J. 94, 17-24
30. Sklarz, B. (1967) Organic chemistry of periodates Q. Rev., Chem. Soc. 21, 3-28
31. West, K. R. and Otto, S. (2005) Reversible covalent chemistry in drug delivery Curr. Drug Discovery Technol. 2, 123-160
32. Kratz, F., Beyer, U., and Schutte, M. T. (1999) Drug-polymer conjugates containing acid-cleavable bonds Crit. Rev. Ther. Drug Carrier Syst. 16, 245-288
33. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2012) Chemistry for peptide and protein PEGylation Adv. Drug Delivery Rev. 64, 116-127
34. Freitas Dda, S. and Abrahao-Neto, J. (2010) Biochemical and biophysical characterization of lysozyme modified by PEGylation Int. J. Pharm. 392, 111-117
35. Freitas Dda, S., Spencer, P. J., Vassao, R. C., and Abrahao-Neto, J. (2010) Biochemical and biopharmaceutical properties of PEGylated uricase Int. J. Pharm. 387, 215-222
36. Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W. J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z. X., Modi, M. W., Farid, A., Berthold, W., and Graves, M. (2001) Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjugate Chem. 12, 195-202
37. Xia, J. H., Zhang, S. D., Li, Y. L., Wu, L., Zhu, Z. J., Yang, X. W., Zeng, H. W., Li, H. L., Wang, N., Steinmetz, A., and Zhang, W. D. (2012) Sesquiterpenoids and triterpenoids from Abies holophylla and their bioactivities Phytochemistry 74, 178-184
38. Bertolotto, A., Gilli, F., Sala, A., Capobianco, M., Malucchi, S., Milano, E., Melis, F., Marnetto, F., Lindberg, R. L., Bottero, R., Di Sapio, A., and Giordana, M. T. (2003) Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients Neurology 60, 634-639
39. Bitsch, A., Dressel, A., Meier, K., Bogumil, T., Deisenhammer, F., Tumani, H., Kitze, B., Poser, S., and Weber, F. (2004) Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b J. Neurol. 251, 1498-1501
40. Reske, D., Walser, A., Haupt, W. F., and Petereit, H. F. (2004) Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment Acta Neurol. Scand. 109, 66-70
41. Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G., and Richette, P. (2012) Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents Expert Opin. Drug Delivery 9, 1319-1323
42. Sundy, J. S., Baraf, H. S., Yood, R. A., Edwards, N. L., Gutierrez-Urena, S. R., Treadwell, E. L., Vazquez-Mellado, J., White, W. B., Lipsky, P. E., Horowitz, Z., Huang, W., Maroli, A. N., Waltrip, R. W., 2nd, Hamburger, S. A., and Becker, M. A. (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials JAMA, J. Am. Med. Assoc. 306, 711-720